UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement ...

"On behalf of the entire team, I'm thrilled to welcome Elaine and Kim to QT Imaging," said Dr. Raluca Dinu, CEO of QTI. "They bring deep clinical expertise and leadership that will be critical as we ...

We’re in the midst of a paradigm shift in biomarker science. | The right biomarker signature can de-risk trials, guide ...

Objectives To evaluate prevention strategies, their unintended consequences and modifiable risk factors for sport-related concussion (SRC) and/or head impact risk. Design This systematic review and ...

Cyber Risk Management Strategy Benefits Understanding the value of a cybersecurity risk management strategy goes beyond avoiding fines or checking a box for compliance. A thoughtful, well-executed ...

Gartner predicts that retrieval-augmented generation will play a pivotal role in mitigating issues with developing and deploying GenAI business apps.

The point is simple: risk mitigation isn’t limited to “every other area” of clinical trials. Teams that proactively risk plan their recruitment and enrollment strategy see enrollment success at a ...

Discover notable ways to enhance your clinical development strategy and design for drug development. Learn how to optimise trial design and leverage data effectively for successful outcomes.

The myopic view of compartmentalizing early and late-stage development strategies from functional departments is becoming a way of the past. It’s time to meet a more modern development approach, ...

QI Path is a category-defining risk intelligence platform that empowers organizations in regulated industries to proactively govern operational risk, ensure regulatory compliance, and accelerate ...

Berlin, Germany, May 27, 2025 – Pentixapharm AG, the operating subsidiary of Pentixapharm Holding AG, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, today outlined a new ...

The drawback with this strategy, however, is that since regulators do not yet mandate their assessment for nitrosamine risk, comprehensive or consistent data on the nitrite content of many excipients ...